Equities Analysts Offer Predictions for VYGR Q1 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for Voyager Therapeutics in a research report issued to clients and investors on Tuesday, March 17th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.24) EPS and Q4 2027 earnings at ($0.22) EPS.

Separately, Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $16.50.

Voyager Therapeutics Trading Down 0.5%

Voyager Therapeutics stock opened at $3.74 on Wednesday. The stock has a 50 day moving average of $3.91 and a two-hundred day moving average of $4.19. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $5.55. The stock has a market capitalization of $222.90 million, a price-to-earnings ratio of -1.84 and a beta of 1.32.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.08. The firm had revenue of $13.46 million for the quarter, compared to analysts’ expectations of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.

Insider Activity

In related news, CEO Alfred Sandrock sold 14,197 shares of the stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the transaction, the chief executive officer directly owned 484,060 shares of the company’s stock, valued at $1,834,587.40. This represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 49,783 shares of company stock worth $188,694 in the last quarter. Insiders own 6.39% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC purchased a new position in Voyager Therapeutics in the second quarter worth $50,000. Altshuler Shaham Ltd purchased a new stake in shares of Voyager Therapeutics during the 4th quarter worth $801,000. Erste Asset Management GmbH boosted its position in shares of Voyager Therapeutics by 7.0% during the 4th quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock worth $4,718,000 after purchasing an additional 78,348 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Voyager Therapeutics during the 4th quarter worth $44,000. Finally, Privium Fund Management B.V. grew its stake in shares of Voyager Therapeutics by 111.1% during the 4th quarter. Privium Fund Management B.V. now owns 95,000 shares of the company’s stock worth $373,000 after purchasing an additional 50,000 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Trending Headlines about Voyager Therapeutics

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised several near‑term 2026 quarterly and full‑year EPS forecasts (Q1–Q4 2026 and FY2026 showed modest improvements), signaling improved near‑term expectations and keeping a $25 price target well above the current share price. Article Title
• Neutral Sentiment: Media coverage summarized analyst commentary on healthcare names including Voyager; these pieces provide background and analyst viewpoints but contain no new company‑specific data beyond the HC Wainwright notes. Article Title
• Negative Sentiment: Alongside the near‑term bumps, HC Wainwright trimmed several longer‑term EPS projections for FY2027–FY2030 (notably FY2027–FY2029 and FY2030 adjustments), lowering the multi‑year profitability outlook — a bearish factor for valuation given Voyager’s loss profile and need for clinical/operational execution to realize upside. Article Title

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.